New SERMs in development
- 30 September 2002
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 38, 26-27
- https://doi.org/10.1016/s0959-8049(02)00274-5
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Lasofoxifene (CP-336,156) Protects Against the Age-Related Changes in Bone Mass, Bone Strength, and Total Serum Cholesterol in Intact Aged Male RatsJournal of Bone and Mineral Research, 2001
- Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement TherapyJournal of Clinical Endocrinology & Metabolism, 2001
- Molecular Mechanism of Action at Estrogen Receptor of a New Clinically Relevant Antiestrogen (GW7604) Related to TamoxifenEndocrinology, 2001
- Pyrazole Ligands: Structure−Affinity/Activity Relationships and Estrogen Receptor-α-Selective AgonistsJournal of Medicinal Chemistry, 2000
- Prevention of bone loss by EM-800 and raloxifene in the ovariectomized ratThe Journal of Steroid Biochemistry and Molecular Biology, 2000
- Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.Journal of Ultrasound in Medicine, 1999
- EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometriumThe Journal of Steroid Biochemistry and Molecular Biology, 1999